Website profile

Via Tt

via.tt.se
All articles Clear site filter

Med Via TT kan du planera, skriva, skicka och följa upp ditt pressmeddelande.

  • 68articles · 30d
  • 9+ hour agolatest article
  • Aug 17, 2026earliest in window
  • 99%with images
  • 277avg words
articles per day
Covers
People
Places
Organizations
Categories
  • Economy, Business & Finance 49
  • Finance & Business 44
  • News 26
  • Business & Industrial 15
  • Science & Technology 13
  • Finance 8
  • Medical 7
  • Health & Wellness 7
Site tags

Please confirm you are human

This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.

A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.

Hold with a pointer, or hold Space or Enter.

News

via.tt.se
via.tt.se > pressmeddelande > 4539173 > ennov-appoints-oxana-pickeral-as-chief-executive-officer

Ennov Appoints Oxana Pickeral as Chief Executive Officer | Business Wire

5+ day, 10+ min ago   (1089+ words) Ennov (the “Company”), a global provider of a unified compliance platform that streamlines regulatory, clinical, quality, and pharmacovigilance operations for life sciences and healthcare companies, today announced the appointment of Dr. Oxana Pickeral as Chief Executive Officer. Founder and outgoing…...

Via TT
via.tt.se > pressmeddelande > 4527458 > biocytogen-enters-into-non-exclusive-licensing-agreement-with-qilu-pharmaceutical-for-a-fully-human-vhh-antibody-to-support-innovative-drug-development-in-neuroscience

Biocytogen Enters into Non-Exclusive Licensing Agreement with Qilu Pharmaceutical for a Fully Human VHH Antibody to Support Innovative Drug Development in Neuroscience | Business Wire

1+ week, 5+ day ago   (562+ words) Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, SSE: 688796; HKEX: 02315) today announced that it has entered into a non-exclusive licensing agreement with Qilu Pharmaceutical Co., Ltd. (“Qilu Pharmaceutical”) for a fully human VHH antibody molecule. Under the agreement, Biocytogen will grant Qilu Pharmaceutical…...

Via TT
via.tt.se > pressmeddelande > 4515333 > virtus-respiratory-research-supports-development-of-apollo-therapeutics-apl-10456-from-preclinical-proof-of-concept-to-positive-phase-1-data

VirTus Respiratory Research Supports Development of Apollo Therapeutics’ APL-10456 from Preclinical Proof of Concept to Positive Phase 1 Data | Business Wire

2+ week, 5+ day ago   (236+ words) 26.8.2026 10:00:00 CEST | Business Wire | Press Release VirTus Respiratory Research Ltd, a specialist respiratory contract research organisation (CRO), founded by Imperial College London investigators Professor Sebastian Johnston and Dr Michael Edwards, today highlighted its role in the preclinical development of Apollo Therapeutics…...